Infinity Piotroski F Score

INFI -  USA Stock  

USD 2.29  0.20  9.57%

This module uses fundamental data of Infinity Pharmaceuti to approximate its Piotroski F score. Infinity Pharmaceuti F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Infinity Pharmaceuti. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Infinity Pharmaceuti financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please see Infinity Pharmaceuti Altman Z Score, Infinity Pharmaceuti Correlation, Infinity Pharmaceuti Valuation, as well as analyze Infinity Pharmaceuti Alpha and Beta and Infinity Pharmaceuti Hype Analysis.

Infinity Piotroski F Score 

 
Refresh
Infinity Pharmaceuti Debt Non Current is most likely to decrease significantly in the upcoming years. The last year's value of Debt Non Current was reported at 1.44 Million. Infinity Pharmaceuti Accrued Expenses Turnover is most likely to drop in the upcoming years. The last year's value of Accrued Expenses Turnover was reported at 0.24. The current Cash and Equivalents Turnover is estimated to increase to 0.07, while Operating Margin is projected to decrease to (52.31) .
At this time, it appears that Infinity Pharmaceuti's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
1
Current Return On Assets
Negative
2
Change in Return on Assets
Decreased
3
Cash Flow Return on Assets
Negative
4
Current Quality of Earnings (accrual)
Decreasing
5
Asset Turnover Growth
Increase
6
Current Ratio Change
Increase
7
Long Term Debt Over Assets Change
Higher Leverage
8
Change In Outstending Shares
Decrease
9
Change in Gross Margin
No Change

Infinity Pharmaceuti Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Infinity Pharmaceuti is to make sure Infinity is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Infinity Pharmaceuti's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Infinity Pharmaceuti's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares58 M59.9 M
Sufficiently Down
Increasing
Slightly volatile
Weighted Average Shares Diluted58 M59.9 M
Sufficiently Down
Increasing
Slightly volatile
Net Cash Flow from Operations(38.6 M)(35.7 M)
Significantly Down
Increasing
Very volatile
Total Assets40.4 M39.3 M
Fairly Up
Decreasing
Slightly volatile
Total Liabilities61.7 M62.3 M
Slightly Down
Decreasing
Stable
Current Assets37 M36 M
Fairly Up
Decreasing
Slightly volatile
Current Liabilities16.8 M11 M
Way Up
Decreasing
Slightly volatile
Total Debt1.5 M1.4 M
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.03690.036
Fairly Up
Decreasing
Slightly volatile

Infinity Pharmaceuti F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Infinity Pharmaceuti's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Infinity Pharmaceuti in a much-optimized way.

About Infinity Pharmaceuti Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

(0.39)Share
Infinity Pharmaceuti Book Value per Share is most likely to drop slightly in the upcoming years. The last year's value of Book Value per Share was reported at -0.38

Infinity Pharmaceuti Current Valuation Drivers

We derive many important indicators used in calculating different scores of Infinity Pharmaceuti from analyzing Infinity Pharmaceuti's financial statements. These drivers represent accounts that assess Infinity Pharmaceuti's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Infinity Pharmaceuti's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Net Income Per Employee(1.31 M)(1.9 M)(450.12 K)(1.88 M)(1.76 M)(1.89 M)
Revenue Per Employee811.82 K272.73 K885.84 K121.96 K74.53 K76.5 K
Average Assets176.34 M79.52 M56.84 M62.83 M48.01 M49.27 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(25.46 M)(39.83 M)(10.97 M)(44.33 M)(37.56 M)(40.53 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(25.46 M)(39.83 M)(10.97 M)(44.33 M)(37.56 M)(40.53 M)
Earnings before Tax(30.1 M)(42.55 M)(11.25 M)(47.11 M)(40.49 M)(43.69 M)
Average Equity91.26 M58.45 M50.8 M23.83 M(12.69 M)(13.02 M)
Enterprise Value(12.86 M)75.36 M34.89 M34.8 M119.15 M122.29 M
Free Cash Flow(152.88 M)(36 M)(4.71 M)(43.86 M)(35.78 M)(38.61 M)
Invested Capital46.17 M19.15 M3.88 M18.98 M1.11 M1.14 M
Invested Capital Average52.42 M29 M10.69 M20.72 M13.29 M13.64 M
Market Capitalization67.14 M102.94 M67.1 M54.75 M136.12 M139.7 M
Tangible Asset Value125.66 M59.35 M60.22 M49.01 M39.32 M40.35 M
Working Capital77.8 M46.79 M52.1 M34.88 M24.97 M25.63 M

About Infinity Pharmaceuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Infinity Pharmaceuti's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infinity Pharmaceuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infinity Pharmaceuti based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 11b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta andor gamma isoforms of PI3K Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.

Infinity Pharmaceuti Investors Sentiment

The influence of Infinity Pharmaceuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Infinity. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Infinity Pharmaceuti Implied Volatility

    
  111.55  
Infinity Pharmaceuti's implied volatility exposes the market's sentiment of Infinity Pharmaceuti stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Infinity Pharmaceuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Infinity Pharmaceuti stock will not fluctuate a lot when Infinity Pharmaceuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Infinity Pharmaceuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Infinity Pharmaceuti's short interest history, or implied volatility extrapolated from Infinity Pharmaceuti options trading.

Current Sentiment - INFI

Infinity Pharmaceuti Investor Sentiment

Most of Macroaxis users are currently bullish on Infinity Pharmaceuti. What is your judgment towards investing in Infinity Pharmaceuti? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Infinity Pharmaceuti using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Infinity Pharmaceuti Altman Z Score, Infinity Pharmaceuti Correlation, Infinity Pharmaceuti Valuation, as well as analyze Infinity Pharmaceuti Alpha and Beta and Infinity Pharmaceuti Hype Analysis. Note that the Infinity Pharmaceuti information on this page should be used as a complementary analysis to other Infinity Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Infinity Stock analysis

When running Infinity Pharmaceuti price analysis, check to measure Infinity Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infinity Pharmaceuti is operating at the current time. Most of Infinity Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Infinity Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Infinity Pharmaceuti's price. Additionally, you may evaluate how the addition of Infinity Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Infinity Pharmaceuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Infinity Pharmaceuti. If investors know Infinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Infinity Pharmaceuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Infinity Pharmaceuti is measured differently than its book value, which is the value of Infinity that is recorded on the company's balance sheet. Investors also form their own opinion of Infinity Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Infinity Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Infinity Pharmaceuti's market value can be influenced by many factors that don't directly affect Infinity Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Infinity Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Infinity Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Infinity Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.